{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:00:59Z","timestamp":1760385659150},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Korea Healthcare Technology R&D Project","award":["A120843-1211-0000600"],"award-info":[{"award-number":["A120843-1211-0000600"]}]},{"name":"Ministry for Health and Welfare, Republic of Korea"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clinthera.2018.07.001","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T01:37:21Z","timestamp":1533605841000},"page":"1384-1395","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Population Pharmacokinetic Analysis of Meropenem After Intravenous Infusion in Korean Patients With Acute Infections"],"prefix":"10.1016","volume":"40","author":[{"given":"Yong Kyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaehyun","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang-Jea","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon-Kuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyubok","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Nam","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Sook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bong Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Gook","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungmin","family":"Kiem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.07.001_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2017.09.019","article-title":"The effects of major burn related pathophysiological changes on the pharmacokinetics and pharmacodynamics of drug use: an appraisal utilizing antibiotics","volume":"123","author":"Udy","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0002","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.01.009","article-title":"Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review","volume":"47","author":"Alobaid","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patients\u2014concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0004","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0005","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200868060-00006","article-title":"Meropenem: a review of its use in the treatment of serious bacterial infections","volume":"68","author":"Baldwin","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0006","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijantimicag.2011.04.019","article-title":"Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia","volume":"38","author":"Jaruratanasirikul","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0007","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0091270006291035","article-title":"Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients","volume":"46","author":"Li","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0008","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00228-016-2053-x","article-title":"Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients","volume":"72","author":"Mattioli","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0009","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijantimicag.2006.05.033","article-title":"Population pharmacokinetics of meropenem in febrile neutropenic patient in Korea","volume":"28","author":"Lee","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0010","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2165\/00003088-200645100-00001","article-title":"Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics","volume":"45","author":"Chen","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0011","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40262-014-0209-3","article-title":"Interethnic differences in pharmacokinetics of antibacterials","volume":"54","author":"Tsai","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0012","doi-asserted-by":"crossref","first-page":"e02185","DOI":"10.1128\/AAC.02185-16","article-title":"Population pharmacokinetic analysis of doripenem after intravenous infusion in Korean patients with acute infections","volume":"61","author":"Lee","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0013","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1179\/1973947815Y.0000000033","article-title":"Population pharmacokinetics of levofloxacin in Korean patients","volume":"28","author":"Kiem","year":"2016","journal-title":"J Chemother"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0014","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3947\/ic.2016.48.3.209","article-title":"Population pharmacokinetic analysis of piperacillin\/tazobactam in Korean patients with acute infections","volume":"48","author":"Kim","year":"2016","journal-title":"Infect Chemother"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0015","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP\/SCCM Consensus Conference Committee. American College of Chest Physicians\/Society of Critical Care Medicine","volume":"101","author":"Bone","year":"1992","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0016","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jchromb.2011.03.038","article-title":"A liquid chromatography assay for a quantification of doripenem, ertapenem, imipenem, meropenem concentrations in human plasma: application to a clinical pharmacokinetic study","volume":"879","author":"Dailly","year":"2011","journal-title":"J Chromatoqr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0017","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jac\/42.1.121","article-title":"A rapid high-performance liquid chromatographic assay for cefepime, cefpirome, and meropenem","volume":"42","author":"Ip","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0018","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1208\/ps040427","article-title":"Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis","volume":"4","author":"W\u00e4hlby","year":"2002","journal-title":"AAPS Pharm Sci"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0019","unstructured":"US Food and Drug Administration, Full Prescribing Information for MERREM IV. December\/2016."},{"key":"10.1016\/j.clinthera.2018.07.001_bib0021","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/jac\/dkq317","article-title":"Population pharmacokinetics of meropenem in burn patients","volume":"65","author":"Doh","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0022","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3947\/ic.2016.48.2.81","article-title":"Prolonged versus intermittent infusion of \u03b2-lactams for the treatment of nosocomial pneumonia: a meta-analysis","volume":"48","author":"Lal","year":"2016","journal-title":"Infect Chemother"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0023","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jac\/dkx330","article-title":"Roberts JA. Maximally effective dosing regimens of meropenem in patients with septic shock","volume":"73","author":"Sj\u00f6vall","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0024","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1128\/AAC.00997-16","article-title":"Population pharmacokinetics and dosing regimen optimization of meropenem in cerebrospinal fluid and plasma in patients with meningitis after neurosurgery","volume":"60","author":"Lu","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0025","doi-asserted-by":"crossref","first-page":"e00794","DOI":"10.1128\/AAC.00794-17","article-title":"Population pharmacokinetics of high-dose continuous meropenem and considerations for use in the treatment of infections due to KPC-producing Klebsiella pneumoniae","volume":"61","author":"Cojutti","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0026","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijantimicag.2016.10.018","article-title":"Might real-time pharmacokinetic\/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae","volume":"49","author":"Pea","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0027","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijantimicag.2012.01.002","article-title":"Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study","volume":"39","author":"Kiratisin","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0028","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/mdr.2010.0034","article-title":"Antimicrobial activity of doripenem and other carbapenems against Gram-negative pathogens from Korea","volume":"17","author":"Lee","year":"2011","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0029","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijantimicag.2012.09.007","article-title":"Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region","volume":"41","author":"Kiratisin","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijantimicag.2010.10.024","article-title":"Pharmacodynamic profiling of intravenous antibiotic against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region","volume":"37","author":"Roberts","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0031","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1128\/JCM.03057-14","article-title":"Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs","volume":"53","author":"Patel","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0032","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.06365-11","article-title":"Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification","volume":"56","author":"Esterly","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0033","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13054-017-1829-4","article-title":"Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study","volume":"21","author":"Ehmann","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0034","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00228-016-2172-4","article-title":"Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function","volume":"73","author":"Usman","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1378\/chest.11-1671","article-title":"Subtherapeutic initial \u03b2-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations","volume":"42","author":"Udy","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0036","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T >MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0037","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1345\/aph.1E271","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia","volume":"39","author":"Ariano","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0038","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3947\/ic.2015.47.3.175","article-title":"In vitro antibacterial activity of doripenem against gram-negative blood isolates in a Korean Tertiary care center","volume":"47","author":"Choi","year":"2015","journal-title":"Infect Chemother"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0039","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ijantimicag.2016.08.015","article-title":"Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis","volume":"48","author":"Tsai","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0040","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1128\/AAC.00259-15","article-title":"Population pharmacokinetics and target attainment of meropenem in plasma and tissue of morbidly obese patients after laparoscopic intraperitoneal surgery","volume":"59","author":"Wittau","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0041","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/jac\/dku429","article-title":"Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations","volume":"70","author":"Ramon-Lopez","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2018.07.001_bib0042","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1177\/0091270004268128","article-title":"Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms","volume":"44","author":"Kim","year":"2004","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818302728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818302728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T10:52:37Z","timestamp":1537786357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818302728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0149291818302728"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.07.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population Pharmacokinetic Analysis of Meropenem After Intravenous Infusion in Korean Patients With Acute Infections","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}